Axa S.A. lifted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 188,835 shares of the biopharmaceutical company’s stock after buying an additional 8,014 shares during the period. Axa S.A. owned approximately 0.08% of Incyte worth $11,447,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of INCY. D.A. Davidson & CO. bought a new stake in Incyte in the fourth quarter valued at approximately $265,000. Corient Private Wealth LLC increased its stake in shares of Incyte by 55.9% in the fourth quarter. Corient Private Wealth LLC now owns 8,546 shares of the biopharmaceutical company’s stock worth $537,000 after buying an additional 3,065 shares during the period. Franklin Resources Inc. raised its holdings in Incyte by 28.3% during the 4th quarter. Franklin Resources Inc. now owns 53,757 shares of the biopharmaceutical company’s stock valued at $3,375,000 after buying an additional 11,851 shares during the last quarter. US Bancorp DE boosted its position in Incyte by 2.5% during the 4th quarter. US Bancorp DE now owns 25,004 shares of the biopharmaceutical company’s stock valued at $1,570,000 after buying an additional 600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in Incyte by 172.8% in the 4th quarter. Bank of Nova Scotia now owns 66,956 shares of the biopharmaceutical company’s stock worth $4,204,000 after acquiring an additional 42,415 shares during the last quarter. Institutional investors own 96.97% of the company’s stock.
Insider Buying and Selling at Incyte
In other news, EVP Vijay K. Iyengar sold 15,571 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total value of $1,089,970.00. Following the transaction, the executive vice president now owns 36,701 shares in the company, valued at $2,569,070. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Vijay K. Iyengar sold 15,571 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the completion of the sale, the executive vice president now owns 36,701 shares of the company’s stock, valued at $2,569,070. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Tray sold 572 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the completion of the transaction, the insider now directly owns 24,825 shares in the company, valued at $1,562,485.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,047 shares of company stock worth $2,225,626. 17.50% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Read Our Latest Research Report on INCY
Incyte Stock Performance
Incyte stock opened at $65.83 on Friday. The stock’s 50 day moving average is $64.31 and its 200 day moving average is $59.92. The company has a market capitalization of $14.78 billion, a P/E ratio of 19.95, a PEG ratio of 5.17 and a beta of 0.73. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $70.36. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of $0.78 by ($2.60). The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.01 billion. Incyte had a net margin of 2.52% and a return on equity of 0.75%. Incyte’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, equities research analysts predict that Incyte Co. will post 0.66 earnings per share for the current fiscal year.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Articles
- Five stocks we like better than Incyte
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- What is a support level?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- There Are Different Types of Stock To Invest In
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.